key: cord-0715475-r1op2yew authors: Dessinioti, C.; Garbe, C.; Stratigos, A.J. title: The impact of the COVID‐19 pandemic on diagnostic delay of skin cancer: a call to restart screening activities date: 2021-08-12 journal: J Eur Acad Dermatol Venereol DOI: 10.1111/jdv.17552 sha: d17225871115bcc3155b3308a9d9d5370b9650ff doc_id: 715475 cord_uid: r1op2yew The COVID-19 pandemic has led to delays in diagnosis and treatment of patients with skin cancer: presentational delay of patients to the physician, diagnostic referral delay due to restrictions of diagnostic capacities, and/or treatment delay (decision to defer treatment due to increased risk of COVID-19 transmission or health policy restrictions to treatment capacities). The COVID-19 pandemic has led to delays in diagnosis and treatment of patients with skin cancer: presentational delay of patients to the physician, diagnostic referral delay due to restrictions of diagnostic capacities, and/or treatment delay (decision to defer treatment due to increased risk of COVID-19 transmission or health policy restrictions to treatment capacities). A significant decrease in skin cancer diagnoses during the lockdown months in 2020 has been reported in studies from the UK Northern Cancer Network, 1 and in US dermatology practices. 2 A decrease in skin cancer referrals during the lockdown was reported in a study in the National Cancer Control Program in Ireland. 3 In a survey conducted by the Global Coalition for Melanoma Patient Advocacy, dermatologists across 36 countries estimated that one-fifth (21%) of melanoma cases went undiagnosed and that one-third of skin check appointments were missed due to the pandemic. 4 Furthermore, there are concerns that diagnostic delay may be associated with thicker and higher stage skin tumours. Retrospective single-centre studies in a small number of patients have reported conflicting results on the Breslow thickness of melanomas diagnosed before and after COVID-19 lockdown, with some studies reporting an increase in thickness 5 and others, a decrease. 6 A Spanish modelling study based on the rate of growth of melanomas predicted that with a 1-month diagnostic delay, there would be an upstaging rate of 21%, while with a 3-mongh diagnostic delay, there would be an upstaging in 45% of cases. 7 In another modelling study, for patients with invasive cutaneous melanoma in England, UK, a 3-month delay to diagnosis was predicted to result in a reduction in long-term 10-year cancer-specific net survival ranging from 3.13% in patients 30-39 years old, to 7.32% in patients 70-79, and 12.56% in patients of 80+ age. 8 Table 1 Recommendations on screening for skin cancer during the COVID-19 pandemic Table 1 . 9,10 It has been proposed that in order for skin cancer screening to be costeffective, high-risk individuals should be targeted. This is even more so during the COVID-19 pandemic. In the pre-COVID era, it was reported that even patients diagnosed with melanoma did not perform skin self-examination (SSE) on a regular basis. 11 During the COVID-19 pandemic, more patients may be inclined to perform SSE and to have fewer follow-up clinic visits. In addition, primary care physicians may assist in skin cancer screening during the COVID-10 pandemic to prevent visits to the hospitals after education on whole-body skin examination, on mnemonic signs such as the ABCDE rule and the 'ugly duckling' sign and possibly on the use of dermoscopy. Teleconsultation is advised whenever possible. 9,10 Teledermatology may be used for the triage of individual concerning lesions, and for virtual melanoma checks, especially for those at highest risk of SARS-Cov-2 infection including frail or elderly patients, and those with chronic diseases or immunosuppression. 12 Teledermatology cannot replace medical inspection, dermoscopy and physical examination. However, teledermatology can help identify those patients who should present in person for an examination. In our experience, this is necessary in approximately one-third of patients. Among proactive measures to raise awareness on skin cancer screening and diagnosis during the pandemic, TV spots and social media may bring tangible and user-friendly messages to the public. In conclusion, we have entered a phase of delayed care in the diagnosis and treatment of skin cancer patients due to the Covid-19 pandemic. The actual impact of the pandemic on staging, survival and mortality will continue to be assessed as further empirical evidence accumulates. Once the pandemic is reasonably under control, we should undertake multifaceted efforts to care for those patients who have not been diagnosed or treated. Dr. Garbe reports grants and personal fees from BMS, personal fees from MSD, grants and personal fees from NeraCare, grants and personal fees from Novartis, personal fees from Philogen, grants and personal fees from Roche, grants and personal fees from Sanofi, outside the submitted work. Dr Stratigos reports personal fees and/or research support from Novartis, Roche, BMS, Abbvie, Sanofi, Regeneron, Genesis Pharma, outside the submitted work. Dr Dessinioti has no conflict of interest to declare. Reduction in skin cancer diagnoses in the UK during the COVID-19 pandemic The magnitude of COVID-19's effect on the timely management of melanoma and nonmelanoma skin cancers Response to 'Reduction in skin cancer diagnosis, and overall cancer referrals, during the COVID-19 pandemic' Survey reveals one fifth of melanomas, globally, went undiagnosed during COVID-19 pandemic The impact of the COVID-19 pandemic on the presentation status of newly diagnosed melanoma: a single institution experience Delayed melanoma diagnosis in the COVID-19 era: increased breslow thickness in primary melanomas seen after the COVID-19 lockdown Estimated effect of COVID-19 lockdown on melanoma thickness and prognosis: a rate of growth model Effect of delays in the 2-week-wait cancer referral pathway during the COVID-19 pandemic on cancer survival in the UK: a modelling study Position statement of the EADV Melanoma Task Force on recommendations for the management of cutaneous melanoma patients during COVID-19 Recommendations for skin cancer consultation and surgery during COVID-19 pandemic Patients' views about skin self-examination after treatment for localized melanoma Virtual melanoma checks during a pandemic